The past decade witnessed great progress in multiple myeloma (MM) management, including new agents such as proteasome inhibitors (1, 2) and immuno-modulators (3, 4), immunotherapy targeting myeloma cells such as the monoclonal antibodies targeting CD38 (5) and SLAMF7 (CS-1) (6), anti-BCMA chimeric antigen receptor T (CAR-T) (7, 8), and the emerging XPO1 inhibitor (9), which all have shown to be effective to treat relapsed and refractory myeloma. This evidence concerns the gene SLAMF7 and plasma cell myeloma.